Abstract
According to current knowledge, the IL-23/Th17 axis plays a central role in the pathogenesis of psoriasis, with IL-17 being considered the primary effector cytokine. The role of IL-17 in psoriasis has led to the initiation of testing of IL-17 inhibitors and subsequently secukinumab, ixekizumab, brodalumab and most recently bimekizumab have been introduced into clinical practice.
These drugs are highly effective in alleviating the symptoms of psoriasis (even in its difficult-to-treat forms) and are well tolerated - the most common adverse effects of IL-17 inhibitors include upper respiratory tract infections, candida infections, headache, diarrhoea and neutropenia. Although they are no longer the most recently approved class of drugs, IL-17 inhibitors are still apowerful tool in the psoriasis treatment armamentarium.